Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02314481
Title Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University College, London
Indications

lung non-small cell carcinoma

Therapies

Vemurafenib

Atezolizumab

Alectinib

Ado-trastuzumab emtansine

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST